The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD

American Journal of Gastroenterology

Volumn 106, Issue 3, 2011, Pages 421-431

  Fass, Ronnie ^a   Johnson, David A ^b   Orr, William C ^c   Han, Cong ^d   Mody, Reema ^e   Stern, Kathleen N ^d   Pilmer, Betsy L ^d   Perez, M Claudia ^d  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c LYNN HEALTH SCIENCE INSTITUTE   (United States)

^d TAKEDA PHARMACEUTICALS   (United States)

^e Takeda Pharmaceuticals International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NIGHT SLEEP; NOCTURNAL HEARTBURN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP PATTERN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EFFICIENCY; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; HEARTBURN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 79952359320     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.458     Document Type: Article

References (38)

1. Farup C, Kleinman L, Sloan S et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001;161:45-52. (Pubitemid 32052142)
2. Locke GR III, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56. (Pubitemid 27181367)
3. Population Division UCB (ed). Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: 1 April 2000 to 1 July 2008 (NST-EST2008-01).
4. Dean BB, Aguilar D, Johnson LF et al. The relationship between the prevalence of nighttime gastroesophageal reflux disease and disease severity. Dig Dis Sci 2009;55:952-9.
5. Mody R, Bolge SC, Kannan H et al. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol 2009;7:953-9.
6. Shaker R, Castell DO, Schoenfeld PS et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98:1487-93. (Pubitemid 36875337)
7. Calleja JL, Bixquert M, Maldonado J. Impact of nocturnal heartburn on quality of life, sleep, and productivity: the SINERGE study. Dig Dis Sci 2007;52:2858-65.
8. Dubois RW, Aguilar D, Fass R et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther 2007;25:487-500. (Pubitemid 46184463)
9. Carskadon MA, Dement WC. Cumulative Effects of sleep restriction on daytime sleepiness. Psychophysiology 1981;18:107-13. (Pubitemid 11056810)
10. Dean BB, Crawley JA, Schmitt CM et al. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003;17:1309-17. (Pubitemid 36693732)
11. Manocchia M, Keller S, Ware JE. Sleep problems, health-related quality of life, work functioning and health care utilization among the chronically ill. Qual Life Res 2001;10:331-45. (Pubitemid 33079012)
12. Nocon M, Labenz J, Jaspersen D et al. Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study. Aliment Pharmacol Ther 2009;29:662-8.
13. Buysse DJ, Reynolds CF III, Monk TH et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213. (Pubitemid 19144991)
14. Spiegel BM, Roberts L, Mody R et al. The development and validation of a nocturnal gastro-oesophageal reflux disease symptom severity and impact questionnaire for adults. Aliment Pharmacol Ther 2010;32:591-602.
15. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
16. Wahlqvist P, Carlsson J, Stalhammar NO et al. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD) - results from a crosssectional study. Value Health 2002;5:106-13. (Pubitemid 34274868)
17. Wahlqvist P, Guyatt GH, Armstrong D et al. The Work Productivity and Activity Impairment Questionnaire for patients with Gastroesophageal reflux Disease (WPAI-GERD): responsiveness to change and English language validation. Pharmacoeconomics 2007;25:385-96. (Pubitemid 46744469)
18. Chey W, Huang B, Jackson RL. Lansoprazole and esomeprazole in symptomatic GERD. A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Investig 2003;23:69-84. (Pubitemid 36286708)
19. Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20. (Pubitemid 38020098)
20. Miner P Jr, Orr W, Filippone J et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-9. (Pubitemid 34664773)
21. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall Efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003;18:587-94. (Pubitemid 37186608)
22. Employer Costs for Employee Compensation News Release December 2009. United States Department of Labor, Bureau of Labor Statistics http://www.bls.gov/news.release/ecec.htm.
23. Fass R, Chey W, Zakko S et al. Clinical trial: the Effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009;29:1261-72.
24. Lind T, Havelund T, Carlsson R et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9. (Pubitemid 27433659)
25. Fass R, Shapiro M, Dekel R et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 2005;22:79-94. (Pubitemid 41039696)
26. Johnson DA, Orr WC, Crawley JA et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005;100:1914-22.
27. Johnson DA. Endpoints for the assessment of response to gastroesophageal reflux disease therapy -what are the appropriate measures of " success "? Rev Gastroenterol Disord 2004;4:118-28. (Pubitemid 39302856)
28. McColl E. Best practice in symptom assessment: a review. Gut 2004;53 (Suppl 4):iv49-54. (Pubitemid 38580761)
29. Stone AA, Shiffman S, Schwartz JE et al. Patient compliance with paper and electronic diaries. Control Clin Trials 2003;24:182-99. (Pubitemid 36412017)
30. Revicki DA, Crawley JA, Zodet MW et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1621-30. (Pubitemid 30009080)
31. Revicki DA, Zodet MW, Joshua-Gotlib S et al. Health-related quality of life improves with treatment-related GERD symptom resolution aft er adjusting for baseline severity. Health Qual Life Outcomes 2003;1:73.
32. Chey WD, Mody RR, Wu EQ et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 2009;25:1869-78.
33. Vakily M, Zhang W, Wu J et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009;25:627-38.
34. Lee RD, Vakily M, Mulford D et al. Clinical trial: the Effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment Pharmacol Ther 2009;29:824-33.
35. Lee RD, Mulford D, Wu J et al. The Effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR - evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther 2010;31:1001-11.
36. Peura DA, Metz DC, Dabholkar AH et al. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther 2009;30:1010-21.
37. Johnson DA, Katz PO. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord 2008;8:98-108. (Pubitemid 351947609)
38. Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. Aliment Pharmacol Ther 2005;21:103-8. (Pubitemid 40222963)